Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

Zinger Key Points
  • Protara says that reinduction and planned enhancements to dosing and administration will lead to an increased CR rate at six months.
  • The company plans to explore additional dosing cohorts.

Friday, Protara Therapeutics Inc TARA shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TARA-002 program, the company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations.

Data were derived from three-month evaluable NMIBC patients with CIS pooled across the company’s ADVANCED-1 Phase 1a, Phase 1b-expansion and ADVANCED-2 Phase 2 trials.

The overall three-month complete response (CR) rate before reinduction for 16 evaluable patients treated across the three trials with varying BCG status was 38% (6/16), with a CR rate of 63% (5/8) in CIS-only patients and 13% (1/8) in patients with CIS +Ta/T1. 

The company believes that reinduction and planned enhancements to dosing and administration will lead to an increased CR rate at six months in patients who did not achieve a CR at three months, as reinduction with other immune agents in NMIBC patients with CIS has demonstrated a 30%-50% salvage rate. 

The company plans to explore additional dosing cohorts.

Most reported adverse events were Grades 1 and 2 across all dose levels and treatment-emergent adverse events (TEAEs).

Enrollment continues in the ADVANCED-2 Phase 2 trial of TARA-002 in patients with high-grade NMIBC with BCG-Unresponsive CIS and BCG-Naïve CIS.

The ADVANCED-2 trial design incorporates reinduction and maintenance dosing.

The company expects to share preliminary results from a pre-planned risk-benefit analysis of the ADVANCED-2 trial in ten patients, who are six-month evaluable in the second half of 2024.

Concurrently, Protara Therapeutics reached alignment with the FDA on a registrational path forward for intravenous (IV) Choline Chloride

The company had previously been pursuing an indication in intestinal failure-associated liver disease and, following FDA feedback, will now pursue a broader indication in patients on parenteral nutrition (PN) who are or may become unable to synthesize choline from oral or enteral nutrition sources. 

The company expects to start a registrational trial to support FDA approval of IV Choline Chloride for PN patients in the first half of 2025.

Protara Therapeutics also announced a private placement of 9.14 million shares, pre-funded warrants to purchase 1.7 million, along with warrants to purchase 10.8 million shares.

Each Share, along with its attached Common Warrant, has a purchase price of $4.15, and each Pre-Funded Warrant, along with its attached Common Warrant, has a purchase price of $4.149. Gross proceeds from the private placement are expected to be approximately $45 million.

Price Action: TARA shares are down 5.94% at $3.781 on the last check Friday.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingOfferingsFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!